Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Indexé dans
  • Index Copernic
  • Google Scholar
  • Ouvrir la porte J
  • JournalSeek de génamique
  • Infrastructure nationale du savoir de Chine (CNKI)
  • Bibliothèque de revues électroniques
  • Recherche de référence
  • Université Hamdard
  • EBSCO AZ
  • OCLC-WorldCat
  • Bibliothèque virtuelle de biologie (vifabio)
  • Publons
  • Fondation genevoise pour l'enseignement et la recherche médicale
  • Euro Pub
  • ICMJE
Partager cette page

Abstrait

Palliative Care in Polish Patients with Multiple Sclerosis

Jozef A. Opara, Waldemar Brola and Jaroslaw Szczygiel

Multiple sclerosis is a progressive disease of the central nervous system with unknown aetiology. It most frequently affects young adults and inevitably leads to disability. Despite significantly progressing development of immunomodulatory treatment, access to which in Poland is limited, the number of patients requiring continuous care and being unable to live independently is constantly growing. The specificity of MS symptoms results from damage of almost all functional systems of the nervous system. The physical, mental, cognitive and psychosocial consequences associated with the symptoms significantly decrease the patients' quality of life. Patients with advanced stage of multiple sclerosis actually qualify for palliative care, which in Poland is reserved mainly for oncological patients and rarely for other groups of patients. The Polish legal system does not provide guaranteed benefits for people with MS requiring palliative and hospice care. Therefore, it is necessary to take action aimed at supporting the most disabled patients who are deprived of the modifying treatment and are only left to symptomatic treatment.